

1 High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding
2 domain and nucleoprotein associate with better neutralization.

3
4 Maria G. Noval^{1†}, Maria E. Kaczmarek^{1†}, Akiko Koide^{2,3†}, Bruno A. Rodriguez-Rodriguez^{1†}, Ping
5 Louie^{4†}, Takuya Tada^{1†}, Takamitsu Hattori^{2,5}, Tatyana Panchenko², Larizbeth A. Romero⁵, Kai
6 Wen Teng², Andrew Bazley⁵, Maren de Vries¹, Marie I. Samanovic⁶, Jeffrey N. Weiser¹, Ioannis
7 Aifantis^{2,4}, Joan Cangiarella⁴, Mark J. Mulligan⁶, Ludovic Desvignes^{3,6,7}, Meike Dittmann¹,
8 Nathaniel R. Landau¹, Maria Agüero-Rosenfeld⁴, Shohei Koide^{2,5*}, and Kenneth A. Stapleford^{1*}

9
10 ¹Department of Microbiology, NYU Grossman School of Medicine, New York, NY 10016

11 ²Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016

12 ³Department of Medicine, NYU Grossman School of Medicine, New York, NY 10016

13 ⁴Department of Pathology, NYU Grossman School of Medicine, New York, NY 10016

14 ⁵Department of Biochemistry and Pharmacology, NYU Grossman School of Medicine, New York,
15 NY 10016

16 ⁶New York University Langone Vaccine Center and New York University Grossman School of
17 Medicine, New York, NY 10016.

18 ⁷Office of Science and Research, NYU Langone Health, New York, NY 10016

19

20 Running title: SARS-CoV-2 antibody response in healthcare workers.

21

22 †Contributed equally to this work.

23 *Corresponding authors.

24 **Abstract**

25 Understanding antibody responses to SARS-CoV-2 is indispensable for the development of
26 containment measures to overcome the current COVID-19 pandemic. Here, we determine the
27 ability of sera from 101 recovered healthcare workers to neutralize both authentic SARS-CoV-2
28 and SARS-CoV-2 pseudotyped virus and address their antibody titers against SARS-CoV-2
29 nucleoprotein and spike receptor-binding domain. Interestingly, the majority of individuals have
30 low neutralization capacity and only 6% of the healthcare workers showed high neutralizing titers
31 against both authentic SARS-CoV-2 virus and the pseudotyped virus. We found the antibody
32 response to SARS-CoV-2 infection generates antigen-specific isotypes as well as a diverse
33 combination of antibody isotypes, with high titers of IgG, IgM and IgA against both antigens
34 correlating with neutralization capacity. Importantly, we found that neutralization correlated with
35 antibody titers as quantified by ELISA. This suggests that an ELISA assay can be used to
36 determine seroneutralization potential. Altogether, our work provides a snapshot of the SARS-
37 CoV-2 neutralizing antibody response in recovered healthcare workers and provides evidence that
38 possessing multiple antibody isotypes may play an important role in SARS-CoV-2 neutralization.

39

40 **Keywords:** SARS-CoV-2, COVID-19, antibody, isotype, neutralization.

41

42

43

44

45

46

47 **Introduction**

48 The novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
49 2), has rapidly spread across the globe, leading to Coronavirus Disease 2019 (COVID-19),
50 devastating mortality, and significant impacts on our way of life. One question that still remains is
51 whether those infected by SARS-CoV-2 generate an immune response that will protect them from
52 reinfection¹. Moreover, this question is particularly important for the development of a SARS-
53 CoV-2 vaccine, as an effective vaccine would need to generate a potent neutralizing antibody
54 response and immunological memory to provide long-lasting protection^{2,3}. Thus, it is essential that
55 we carefully study and document the neutralizing antibody responses in recovered individuals.

56 SARS-CoV-2 antibody testing is critical to understanding who has been infected and to
57 provide a picture of seroprevalence in a community⁴⁻⁹. However, while these tests are important
58 and provide a relative antibody titer, they are seen more as a “yes or no” type of answer to whether
59 an individual has been infected. Importantly, these tests do not provide information on whether the
60 SARS-CoV-2-specific antibodies present in serum are protective, including through virus
61 neutralization, and as such, a positive antibody test may give individuals a false sense of
62 “immunity” to the virus.

63 A number of studies have begun to unravel the antibody response to SARS-CoV-2 beyond
64 a simple “yes or no” answer⁹⁻¹⁸. Here, we hypothesized that by examining the antibody profile in
65 patient’s serum in terms of antigens, antibody isotypes (IgG, IgM, and IgA), and neutralization,
66 we would be able to identify specific signatures associated to effective SARS-CoV-2
67 neutralization. In this study, we obtained convalescent serum from 101 SARS-CoV-2 PCR-
68 positive healthcare workers and performed a comprehensive analysis of neutralization of authentic
69 SARS-CoV-2 and a pseudotyped lentivirus as well as serum IgG, IgM, and IgA antibody titers to

70 the SARS-CoV-2 spike receptor-binding domain (RBD) and the nucleoprotein (N) (**Fig. 1a**).
71 Together, this study provides an in-depth look into the SARS-CoV-2 neutralizing antibody
72 response in recovered individuals and highlights the role of multiple antibody isotypes in the
73 development of a potent neutralizing antibody response.

74

75 **Methods**

76 **Serum samples.** Serum was collected from 101 healthcare workers from NYU Langone who had
77 laboratory evidence of COVID-19 (PCR-positive) and were at least 21-28 days post symptoms or
78 PCR test. Healthy control sera were collected from patients through the NYU Vaccine Center. All
79 patients gave written consent and all samples were deidentified for this study under IRB #i20-
80 00595 (SARS-CoV-2 infected) and IRB #s18-02037 (healthy controls).

81 **Plasmids** For pseudotyped virus generation: To construct the SARS-CoV-2 Δ 19 expression
82 vector pcCOV2- Δ 19.S, a codon-optimized DNA sequence was synthesized encoding the SARS-
83 CoV-2 Spike (Wuhan-Hu-1/2019). An amplicon was amplified encoding the S protein with a 19
84 amino acid truncation of the cytoplasmic tail using primers containing flanking 5'-KpnI and 3'-
85 XhoI sites and cloned into pcDNA6 (Invitrogen, Inc.). To construct the ACE2 expression vector
86 pLenti.ACE2-HA, the ACE2 coding sequence was amplified from an ACE2 cDNA (Origene Inc)
87 using primers with flanking 5'-XbaI and 3'-Sall sites and cloned into pLenti.CMV.GFP.puro. For
88 RBD ELISA: The nucleotide sequence of the RBD of SARS-CoV-2 isolate Wuhan-Hu-1 (residues
89 328-531) was obtained from a GenBank entry MN908947.3. A codon-optimized gene encoding
90 the RBD with a hexa-histidine tag (His₆-tag) and biotinylation tag (Avi-tag) at the C terminus was
91 synthesized (Integrated DNA Technologies) and cloned into the pBCAG mammalian expression
92 vector.

93 **Cells and virus.** Vero E6 cells (ATCC CRL-1586) were maintained in Dulbecco's Modified
94 Eagle's Medium (DMEM, Corning) supplemented with 10% fetal bovine serum (FBS, Atlanta
95 Biologics) and 1% nonessential amino acids (NEAA, Corning). Human embryonic kidney (HEK)
96 293T cells were maintained in DMEM supplemented with 10% FBS, and 1%
97 penicillin/streptomycin (P/S). To generate 293T stably expressing ACE2 (ACE2-293T cells),
98 293T cells were transfected with pLenti.ACE2-HA DNA by lipofection with lipofectamine 2000
99 (Invitrogen). After 2 days, the cells were selected in DMEM supplemented with 10% FBS, 1%
100 P/S, and 1 µg/ml of puromycin. Single cell clones were expanded and analyzed by flow cytometry
101 for ACE2 expression and a single clone was chosen for subsequent use. Expi293T cells (Thermo
102 Fisher) were maintained in Expi293 Expression Medium (Thermo Fisher). All cells were
103 maintained at 37°C with 5% CO₂ and confirmed mycoplasma free.

104 SARS-CoV-2, isolate USA-WA1/2020¹⁹ (BEI resources # NR52281, a gift from Dr. Mark
105 Mulligan at the NYU Langone Vaccine Center) was amplified once in Vero E6 cells (P1 from the
106 original BEI stock). Briefly, 90-95% confluent T175 flask (Thomas Scientific) of Vero E6 (1x10⁷
107 cells) was infected with 10 µL of the BEI stock in 3 mL of infection media (DMEM, 2% FBS, 1%
108 NEAA, and 10 mM HEPES, pH 7.0) for 1 hour. After 1 hour, 15 ml of infection media was added
109 to the inoculum and cells were incubated 72 hrs at 37 °C and 5% CO₂. After 72 hrs, the supernatant
110 was collected and the monolayer was frozen and thawed once. Both supernatant and cellular
111 fractions were combined, centrifuged for 5 min at 1200 rpm, and filtered using a 0.22 µm Steriflip
112 (Millipore). Viral titers were determined by plaque assay in Vero E6 cells. In brief, 220,000 Vero
113 E6 cells/well were seeded in a 24 well plate, 24 hrs before infection. Ten-fold dilutions of the virus
114 in DMEM were added to the Vero E6 monolayers for 1 hour at 37 °C. Following incubation, cells
115 were overlaid with 0.8% agarose in DMEM containing 2% FBS and incubated at 37 °C for 72 hrs.

116 The cells were fixed with 10% formalin, the agarose plug removed, and plaques visualized by
117 crystal violet staining. All experiments with authentic SARS-CoV-2 were conducted in the NYU
118 Grossman School of Medicine ABSL3 facility.

119 **Pseudotyped virus preparation.** Pseudotyped virus was produced by calcium phosphate
120 cotransfection of 293T cells with pMDL, plenti.GFP-NLuc, pcSARS-CoV-2-SΔ19 and pcRev at a
121 ratio of 4:3:4:1. The supernatant was harvested 2 days post-transfection, passed through an 0.22
122 μm filter and then pelleted by ultracentrifugation for 90 min at 30,000 rpm in an SW40.1 rotor.
123 The pellet was resuspended in 1/10th the original volume of DMEM supplemented with 10% FBS
124 and frozen at -80°C in aliquots.

125 **SARS-CoV-2 neutralization assay.** Vero E6 cells (30,400 cells/well) were seeded in a 96 well
126 plate 24 hrs before infection so that a monolayer was present the following day. Serum samples
127 from COVID-19 convalescent individuals and healthy donors were two-fold serially diluted
128 (spanning from 1:10 to 1:10,240) in DMEM (Corning), 1% NEAA (Corning) and 10 mM HEPES
129 (Gibco). Diluted serum samples were mixed 1:1 (vol/vol) with SARS-CoV-2 virus (6.8 x 10³
130 PFU/ml), and incubated 1 h at 37 °C. During the incubation period, Vero E6 monolayers were
131 washed once with DMEM (Corning) to remove any serum present in the media that could interfere
132 with the assay. After incubation, 100 μl of the serum:SARS-CoV-2 mixtures were added to the
133 Vero E6 monolayers, and cells were incubated at 37°C. Cells were monitored every day for
134 cytopathic effects (CPE) induced by viral infection, and at 5 days post infection cells were fixed
135 in 10% formalin solution (Fisher Scientific) for 1 hr. Cells were then stained by adding 50 μl
136 crystal violet/well and incubated for 30 min. Each well was scored as “0” if there was no monolayer
137 left, “0.5” if there was some monolayer and the well was clearly infected, or “1” if the monolayer
138 was intact. The minimum inhibitory concentration (MIC) was defined as the minimal serum

139 dilution in which the cell monolayer was intact (score = 1). Each serum sample was measured in
140 technical duplicates.

141 **Pseudotype virus neutralization assay.** To determine neutralizing serum titers, ACE2-293T cells
142 were plated in 96 well tissue culture dishes at 10,000 cells/well. The following day, 2-fold dilutions
143 of the donor sera were made in culture medium spanning a range from 1:10 to 1:10240. Each
144 dilution (50 μ l) was mixed with 5 μ l SARS-CoV-2 S Δ 19 lentiviral pseudotype. The mixtures were
145 incubated for 30 min at room temperature and then added to the plated ACE-2 293T cells. The
146 plates were cultured for two days at 37°C with 5% CO₂ after which the supernatant was removed
147 and replaced with 50 μ l Nano-Glo Luciferase Substrate (Promega, Inc.). Light emission was
148 measured in an Envision 2103 Multi-label plate reader (PerkinElmer, Inc.).

149 **SARS-CoV-2 Nucleoprotein ELISA.** Serum IgG, IgA, and IgM antibodies to the SARS-CoV-2
150 nucleoprotein were tested using the SARS-CoV-2 IgG, IgA and IgM ELISA kits manufactured by
151 Virotech Diagnostics GmbH for Gold Standard Diagnostics (Davis, CA) following the
152 manufacturer's instructions. For the detection of IgG and IgA, serum samples were diluted 1:100
153 in dilution buffer and for IgM, serum samples were diluted 1:101 in RF-Adsorption dilution buffer
154 mixture and incubated at room temperature for 15 min before being added to the wells. Results are
155 reported qualitatively as negative (<9.0 units), equivocal (9.0-11.0 units), and positive (>11.0
156 units).

157 **SARS-CoV-2 spike receptor-binding domain (RBD) purification and ELISA.** The Expi293F
158 cells (Thermo Fisher) were transiently transfected with the expression vector using the
159 ExpiFectamine™ 293 Transfection Kit (Thermo Fisher, A14524) and the Expi293 Expression
160 Medium (Thermo Fisher, A14351). The transfected cells were cultured at 37 °C with 8% CO₂ for
161 7 days. The culture supernatant was harvested by centrifugation, supplemented with protease

162 inhibitors and clarified by further centrifugation at 8,000 rpm for 20 min and filtration through a
163 0.22 μ m filter. The supernatants were dialyzed into 20 mM sodium phosphate pH 7.4 with 500
164 mM sodium chloride and the recombinant RBD was purified by immobilized metal ion affinity
165 chromatography (IMAC) using a HisTrap excel column (GE Healthcare). The purified protein was
166 biotinylated using the *E. coli* BirA enzyme produced in house in the presence of 10 mM ATP and
167 0.5 mM biotin. The RBD protein was purified by IMAC and dialyzed against PBS and stored at -
168 80 °C. High purity of the purified protein was confirmed using SDS-PAGE, and analysis by size
169 exclusion chromatography using a Superdex 75 10/300 Increase column (GE Healthcare), which
170 showed a single, monodisperse peak consistent with its molecular mass (**Extended Data Fig. 1A**
171 **and B**).

172 For the ELISA, the wells of 384-well ELISA plates (NUNC Maxisort cat# 464718) were
173 coated with 15 μ l of 4 μ g/ml neutravidin (ThermoFisher cat # 31000) for one hour at room
174 temperature (R.T.) in a humidified chamber. The wells were washed with 100 μ l PBST (PBS
175 containing 0.1 % Tween 20) (ThermoFisher, cat# BP337-500) three times using a BioTek 405TS
176 plate washer housed in a BSL-2 biosafety cabinet. The wells were blocked with 0.5 % BSA
177 (Gemini Bio cat# 700-100P, skim milk was not used for blocking because milk can contain biotin
178 that would inhibit antigen immobilization) in PBS overnight at 4 °C. After removing the blocking
179 buffer, 15 μ l of 20 nM RBD-His₆-Avi-biotin in PBS was added to each well using a Mantis
180 dispenser (Formulatrix). The plates were incubated at R.T. in a humidified chamber for 20 min,
181 and the wells were washed with 100 μ l PBST three times using the plate washer. The wells were
182 further blocked with 15 μ l of 10 μ M biotin in 3% skim milk in PBST (Sigma, cat# 1.15363.0500)
183 for ten min at R.T. in order to block unsaturated neutravidin.

184 Serum samples were heat-treated at 56°C for one hour⁹ and diluted 158-fold in 1% skim
185 milk in PBST and placed in a 96-well polypropylene plate (ThermoFisher, cat # AB-0796), which
186 served as a master plate. The following sample handling was performed using a Hudson SOLO
187 liquid handler housed in a BSL-2 biosafety cabinet. Twelve microliters of diluted serum were
188 transferred per well of an RBD-immobilized 384-well plate after removing the biotin solution. To
189 prepare 500-fold diluted samples, 8.22 µl of the diluent (1 % skim milk in PBST) was first
190 dispensed into a well to which 3.78 µl of diluted serum from the master plate was added. After 2
191 hours of incubation at R.T., the plate was washed with PBST three times using the plate washer.
192 15 µl of secondary antibody (anti human Fab-HRP: Jackson ImmunoResearch, cat# 109-035-097;
193 anti human IgG-HRP: Sigma, cat# A6029-1ML; anti human IgM-HRP: Jackson ImmunoResearch,
194 cat# 109-035-129; and anti-human IgA-HRP: Jackson ImmunoResearch, cat# 109-035-011;
195 x1/5000 diluted in 1 % milk in PBST) was added using the Mantis dispenser and incubated for one
196 hour at R.T. After washing the plate with PBST three times and then with PBS three times, 25 µl
197 of the substrate (SIGMAFAST™ OPD; Sigma P9187-50SET) was added into the wells using the
198 Mantis dispenser. Subsequently, the stop solution (25 µl of 2 M HCl) was added using the Mantis
199 dispenser. The dispenser was programmed in such a way that the reaction in each well was stopped
200 after 10 min. Absorbance at 490 nm was measured using a BioTek Epoch 2 plate reader. All
201 samples were analyzed two independent times to identify outliers. Those yielding inconsistent
202 results in both assays were excluded from analysis (Sample 76 and 86, **Extended Data Table 1**).
203 Thresholds were determined comparing the 101 SARS-CoV-2 PCR positive samples at two
204 dilutions 1/158 and 1/500 and compared with 43 SARS-CoV-2 PCR negative individuals. The
205 cutoff values were defined as the mean plus three times the standard deviation (SD) of the negative

206 control samples. Results were reported as positive if the values are > 1.091 for IgG, > 0.256 for
207 IgA and > 0.694 for IgM (**Extended Data Fig. 1C**).

208 **Data analysis and statistics.** All experiments were performed in technical duplicates and data
209 analysis and statistics were performed using GraphPad Prism (Version 8.4.3), R Studio (Version
210 1.2.5001), and R (Version 3.6.3).

211 **Data availability.** Data that supports all figures, extended data, and analysis is found in Extended
212 Data Table 1.

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229 **Results**

230 **SARS-CoV-2 seroneutralization capacity is low in the majority of individuals.**

231 To better understand the human SARS-CoV-2 neutralizing antibody response in
232 convalescent patients, we obtained serum from 101 COVID-19-recovered New York City
233 healthcare workers who had experienced symptoms and had tested positive (by PCR testing) for
234 SARS-CoV-2 in March 2020 (**Fig. 1a** and **Extended Data Table 1**). To begin, we assessed how
235 well each individual's serum was able to neutralize both authentic SARS-CoV-2 (isolate USA
236 WA01/2020), and a lentiviral pseudotyped virus bearing the SARS-CoV-2 Spike protein
237 (pseudotyped virus) *in vitro*. Pseudotyped viruses are a safe alternative to authentic virus assays²⁰,
238 and can therefore be employed by a greater number of research institutes and clinical laboratories
239 to assess neutralization of convalescent serum. However, several studies have shown differences
240 in sensitivity between neutralization of authentic SARS-CoV-2 and specific pseudotyped
241 viruses^{21,22}. Thus, we set out to determine serum neutralization capacity using both our in-house
242 lentiviral pseudotyped virus and the WA01/2020 strain of SARS-CoV-2.

243 For the neutralization assays performed with authentic SARS-CoV-2 virus we determined
244 the minimum inhibitory concentration (MIC), calculated as the minimum serum dilution at which
245 serum is fully-protective (**Extended Data Table 1**). For the neutralization experiments performed
246 with the pseudotyped virus, we used a reporter pseudotyped virus expressing luciferase which
247 allows for the calculation of the IC₉₀ and the midpoint transition (IC₅₀) (**Extended Data Fig. 2** and
248 **Extended Data Table 1**). Using these systems, we found that neutralization of the authentic
249 SARS-CoV-2 and the pseudotyped virus was positively correlated (**Fig. 1b**, $R^2 = 0.49$, $p < 0.0001$).
250 Moreover, the SARS-CoV-2 neutralizing antibody response could be broken into three categories
251 (**Fig. 1c**). Using $1/\text{MIC}$ and $1/\text{IC}_{90}$ we find the majority of infected individuals (~75%) had a low

252 neutralization capacity, roughly 20% of individuals had intermediate neutralization and only a
253 select few (~5-6%) had high neutralization of the authentic virus. When comparing pseudotyped
254 virus to authentic SARS-CoV-2 virus neutralization, there was no significant difference in the
255 proportion of individuals assigned as low or intermediate (**Fig. 1c**). In contrast, there is a significant
256 difference between the percentage of individuals deemed high neutralizers using authentic SARS-
257 CoV-2 versus pseudotyped virus (**Fig. 1c and d, p=0.02**). These results validate the use of the
258 pseudotyped virus as an efficient alternative to determine the neutralizing potential of serum. But
259 they also suggests that authentic SARS-CoV-2 virus may be better able to detect potent
260 neutralizing serums, which has implications for the selection of donors for passive immunization
261 therapy.

262 Finally, because samples were collected from individuals at varying times post onset of
263 symptoms, it may be expected that the proportion of highly or moderately neutralizing sera would
264 decrease over time. However, we found that there was no particular pattern in this cohort.
265 Individuals with low, medium, and high neutralizing sera determined using authentic SARS-CoV-
266 2 are found between 32 and 57 days (**Fig. 1e**). Together, these results show that at the time points
267 we analyzed (32-57 days post symptom onset), serum SARS-CoV-2 neutralizing antibody capacity
268 is low in most recovered individuals.

269 **Human SARS-CoV-2 infection generates antigen-specific, multi-isotype antibody response.**

270 Given the broad neutralization capacity observed in this cohort, we were interested in
271 examining the antibody profile of each individual. It is not uncommon that antibody responses are
272 skewed toward one or a few viral proteins^{10,23}. If this is the case, using a single antigen may result
273 in a biased test that inadequately detects antibodies produced by convalescent individuals. Thus,
274 we quantified serum antibody IgG, IgA, and IgM titers by ELISA, focusing on antibodies

275 generated to two SARS-CoV-2 antigens (**Extended Data Table 1**). First, we used the Gold
276 Standard ELISA assay currently deployed at the Tisch Hospital Clinical Labs in New York City
277 which uses the nucleoprotein (N). Second, we developed an in-house ELISA for the SARS-CoV-
278 2 Spike receptor-binding domain (RBD) (**Extended Data Fig. 1**). If antibody titers against Spike
279 RBD and N correlate, this suggests that individuals mount a uniform response to both these
280 antigens. A lack of correlation suggests that individuals mount a skewed response toward one of
281 these antigens preferentially.

282 When we compared the isotype responses to anti-RBD and anti-N directly, we found that
283 IgG correlated the strongest ($R^2 = 0.51$) followed by IgA ($R^2 = 0.23$) and IgM ($R^2 = 0.21$) (**Fig.**
284 **2a-c, left panels**). The percentage of IgG and IgM positive individuals, as detected by reactivity
285 against RBD or N, was similar (**Fig. 2a and b, right panels**). Strikingly, the majority of individuals
286 with positive titers of IgA to the Spike RBD were largely IgA-negative for N (**Fig. 2c, left panel**).
287 This translated to a significant difference in IgA detection between the Gold Standard test and our
288 in-house ELISA (**Fig. 2c, right panel**, $p = 2 \times 10^{-16}$), and suggests that the IgA response is largely
289 skewed towards the Spike RBD in comparison to N (**Fig. 2c**). It is possible that days post symptom
290 onset plays a role in both serum antibody titers and the relative percentage of IgG, IgM and IgA
291 positive people. Within our cohort we observed no relationship between time post symptom onset
292 and antigen-specific antibody isotype titers (**Extended Data Fig. 3**), even finding IgM present at
293 50 days post infection (**Extended Data Fig. 3B**). Together these results suggest that the antibody
294 isotype response to SARS-CoV-2 may be antigen-specific, with IgA skewed towards the RBD.
295 **SARS-CoV-2 neutralization best correlates with RBD antibody response.**

296 To better understand how each antigen-specific antibody isotype correlated with
297 neutralization, we compared the ELISA assay antibody titers with virus neutralization. While all

298 anti-RBD isotype titers correlated similarly with the neutralization level of the authentic SARS-
299 CoV-2 ($R^2 = 0.4786 - 0.5194$) (**Fig. 3a**), we found that pseudotyped virus neutralization correlated
300 best with IgG titers ($R^2 = 0.4561$) compared with IgA ($R^2 = 0.2556$) or IgM ($R^2 = 0.2391$) (**Fig.**
301 **3b**). One explanation for these findings may be that there are molecular differences in folding
302 between the RBD of the authentic virus, pseudotyped virus, and purified RBD such that they are
303 recognized differently by antibody isotypes in these assays^{24,25}. Interestingly, with the exception
304 of anti-N IgG antibodies for the authentic virus ($R^2 = 0.5277$; $R^2 = 0.255$), other anti-N isotype
305 titers showed weaker correlations for either the authentic SARS-CoV-2 virus or the pseudotyped
306 virus (**Extended Data Fig. 4**). These data suggest that ELISA methods based on the RBD may
307 benefit from detection of additional isotypes, rendering them better suited as predictors of sera
308 neutralization.

309 **Robust SARS-CoV-2 neutralization associates with high-titer, multi-isotype antibody**
310 **responses.**

311 Next, we delineated what separates our highest neutralizers from the remainder of the
312 cohort using the data collected on antigen-specific antibody isotype titers. To do so, we employed
313 a holistic approach and compared the IgG, IgM and IgA titers for both anti-Spike RBD and anti-
314 N antibodies against neutralizations level (**Fig. 4a and b**). This revealed that the highest overall
315 neutralizers (MIC higher or equal to 1/640) had higher titers of IgG, IgM and IgA raised against
316 both Spike RBD and N (**Fig. 4a and b**, red bar). The spike protein is the major determinant for
317 virus neutralization and resides on the outside of the viral particle, exposed to the immune
318 recognition. Consequently, we found stronger correlations between Spike-RBD isotypes compared
319 with N isotypes, when comparing each individual's IgG, IgM or IgA (anti-Spike RBD and N)
320 against each other (**Fig. 4c and d**). However, in most cases the high neutralizers (red circles) had

321 the highest antibody titers for all isotypes (**Fig. 4c and 4d**). These data suggest that mounting a
322 robust antibody response, consisting of diverse isotypes, leads to efficient neutralization.

323 **Recovered individuals have multiple combinations of anti-SARS-CoV-2 serum antibodies.**

324 Finally, given that having multiple isotypes associate with higher neutralization, we were
325 interested in understanding the anti-RBD and N antibody signatures present in individuals and how
326 they correlated with neutralization. Therefore, we classified whether the presence or absence of
327 certain antigen-specific antibody isotypes (based on ELISA cutoffs) related to neutralization level.
328 The 101 COVID-19 patients comprised 21 different antibody combinations, or “clusters” (**Fig.**
329 **5a**), ranging from being positive for all six antibodies (N/RBD IgG, IgA, IgM) to three individuals
330 who did not have antibodies to neither N or RBD (**Fig. 5a and b, Cluster U**). We found that 4 out
331 of the 6 healthcare workers with high neutralizing titers (MIC = 1/640 – 1/2560) had sera that
332 tested positive for all three isotypes (IgA, IgG, and IgM) responsive against both Spike RBD and
333 N (**Fig. 5b, Cluster A**). However, two individuals with high neutralizing titers (#61 and 67)
334 contained a combination of isotypes that were shared with both medium and low neutralizers (**Fig.**
335 **5b, Clusters C and D**). Interestingly, Cluster B, which only lacks IgM against the RBD does not
336 have high neutralization compared with Clusters A, C, and D, suggesting that specific antibody
337 combinations and/or titers may be necessary for maximum neutralization. Finally, the majority of
338 individuals had at least IgG and IgA directed against the RBD accompanied by IgG to N (**Fig. 5b**).
339 Taken together, these results suggest that having IgG alone may not be enough for efficient
340 neutralization, while having multiple isotypes at high titers present in serum leads to more potent
341 SARS-CoV-2 neutralization.

342

343

344 **Discussion**

345 Understanding the antibody response and potential immunity to SARS-CoV-2 is critical
346 for global public health and the development of efficacious vaccines^{1,3,26}. In this study, we
347 performed a comprehensive analysis of the SARS-CoV-2-specific antibody response in 101
348 convalescent healthcare workers serum samples. We determined the neutralization capacity of the
349 sera using both authentic virus and pseudotyped particles, quantified the titers of three antibody
350 isotypes (IgG, IgM, and IgA) to both the spike receptor-binding domain and the nucleoprotein,
351 and investigated the correlation of neutralization and antibody levels. We found, that the serum
352 SARS-CoV-2 neutralizing antibody capacity was low for the majority of recovered individuals. In
353 extreme cases, we detected no antibodies against SARS-CoV-2 Spike RBD or N in three
354 individuals. These observations are in line with previously published studies and may suggest that
355 those infected do not produce efficient neutralizing antibodies or neutralizing antibodies rapidly
356 wane by the time samples are collected^{16,27,28,29}. Detailed longitudinal studies are beginning to
357 emerge, showing that serum antibody levels are relatively stable or decrease over time³⁰⁻³². In-line
358 with our results these studies find a positive correlation between IgG titers and
359 neutralization^{31,32}. Further characterization of neutralization at early and late timepoints is
360 necessary to correlate antibody titer stability to viral protection. However, it is essential to keep in
361 mind that, while neutralization titers can be quantified by reliable laboratory assays, we do not
362 know the overall protective capacity of antibodies against SARS-CoV-2 in patients. Thus, those
363 with low neutralizing capacities in the lab ($MIC < 1/80$) could be efficiently protected from SARS-
364 CoV-2 reinfection. Detailed studies monitoring initial and possible reinfections along with the
365 antibody response are crucial to understand immunity to SARS-CoV-2.

366

367 To further understand the composition of convalescent sera, we quantified the amounts of IgG,
368 IgA, and IgM targeting the spike protein RBD and N. We found 21 different antibody
369 combinations that did not directly correlate with days post symptom onset, yet did associate with
370 antibody neutralization. Of these combinations, the majority of individuals fell into four distinct
371 clusters comprised of different antigen-specific isotypes. It remains to be elucidated how these
372 clusters are generated and why certain clusters elicit potent SARS-CoV-2 neutralization (Cluster
373 A) and others do not (Cluster B). Since we use a targeted approach focusing on only two antigens
374 and specific epitopes, it is possible that there are other anti-SARS-CoV-2 antibodies that bind viral
375 particles and impact neutralization³³.

376 Interestingly, we found high quantities of IgM present in some individuals from 32 to 50
377 days post symptom onset. These findings are intriguing since IgM antibodies are usually
378 considered as a marker of a recent infection and their circulating titers are thought to decrease as
379 class switching occurs to IgG and IgA. This observation is of importance for determining the
380 relative time of infection. In this situation, looking at multiple isotypes including IgA as well as
381 multiple antigens may be beneficial in determining the relative infection timeline. Along these
382 lines, we also found that individuals having multiple antibodies isotypes to both RBD and N had
383 the best neutralization. Moreover, we found that individuals who had IgG in combination with
384 IgM and IgA against the RBD had the greatest neutralization capacity, suggesting that the
385 generation of combinations of antibody isotypes against the RBD may provide the best
386 neutralization. It has been shown that severity of disease can play an important role in the antibody
387 response and it may be that in these individuals, disease is a driver for multiple isotypes and
388 increased neutralization^{15,34}. Thus, understanding how enhanced disease burden leads to the
389 generation of multiple neutralizing isotypes will be crucial for vaccine development.

390 These results, particularly the presence of individuals with low neutralizing antibodies are
391 interesting as each individual in our cohort has recovered from SARS-CoV-2 infection. This
392 observation suggests that either we missed the period of robust neutralizing antibody production
393 in certain individuals or other mechanisms, such as potent SARS-CoV-2 specific T-cell
394 responses^{35,36,37-41}, provided effective viral clearance and immunity. Future studies coupling
395 assessment of antibody and T-cell responses with key clinical information (age, sex, severity of
396 symptoms) will be essential to fully understand this complex immune response. Moreover, these
397 results also highlight the need to study the SARS-CoV-2 genetics as the virus encodes multiple
398 undefined accessory proteins that could impact the immune response during infection.
399 Additionally, longitudinal studies are necessary to fully understand the complex immune response
400 to SARS-CoV-2 in the hopes to contain this virus and to prepare for the emergence of related
401 viruses.

402

403 **Acknowledgements**

404 We thank all the volunteers for participation in this study and the members of the NYU Vaccine
405 Center and NYU Langone Health for obtaining these samples. We thank Drs. Chi Yun and Adriana
406 Heguy for access to the Mantis instrument. We thank members of each lab for helpful comments
407 and discussion on the study and manuscript.

408

409

410

411

412

413 **References**

- 414 1 Vabret, N. *et al.* Immunology of COVID-19: Current State of the Science. *Immunity* **52**,
415 910-941, doi:10.1016/j.immuni.2020.05.002 (2020).
- 416 2 Bar-Zeev, N. & Moss, W. J. Encouraging results from phase 1/2 COVID-19 vaccine
417 trials. *Lancet*, doi:10.1016/S0140-6736(20)31611-1 (2020).
- 418 3 Sempowski, G. D., Saunders, K. O., Acharya, P., Wiehe, K. J. & Haynes, B. F. Pandemic
419 Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. *Cell*
420 **181**, 1458-1463, doi:10.1016/j.cell.2020.05.041 (2020).
- 421 4 Stadlbauer, D. *et al.* SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a
422 Serological Assay, Antigen Production, and Test Setup. *Curr Protoc Microbiol* **57**, e100,
423 doi:10.1002/cpmc.100 (2020).
- 424 5 Biggs, H. M. *et al.* Estimated Community Seroprevalence of SARS-CoV-2 Antibodies -
425 Two Georgia Counties, April 28-May 3, 2020. *MMWR Morb Mortal Wkly Rep* **69**, 965-
426 970, doi:10.15585/mmwr.mm6929e2 (2020).
- 427 6 Luchsinger, L. L. *et al.* Serological Analysis of New York City COVID19 Convalescent
428 Plasma Donors. *medRxiv*, doi:10.1101/2020.06.08.20124792 (2020).
- 429 7 Krammer, F. & Simon, V. Serology assays to manage COVID-19. *Science* **368**, 1060-
430 1061, doi:10.1126/science.abc1227 (2020).
- 431 8 Havers, F. P. *et al.* Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the
432 United States, March 23-May 12, 2020. *JAMA Intern Med*,
433 doi:10.1001/jamainternmed.2020.4130 (2020).
- 434 9 Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans.
435 *Nat Med* **26**, 1033-1036, doi:10.1038/s41591-020-0913-5 (2020).
- 436 10 Premkumar, L. *et al.* The receptor binding domain of the viral spike protein is an
437 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci*
438 *Immunol* **5**, doi:10.1126/sciimmunol.abc8413 (2020).
- 439 11 Seydoux, E. *et al.* Characterization of neutralizing antibodies from a SARS-CoV-2
440 infected individual. *bioRxiv*, doi:10.1101/2020.05.12.091298 (2020).
- 441 12 Jiang, H. W. *et al.* SARS-CoV-2 proteome microarray for global profiling of COVID-19
442 specific IgG and IgM responses. *Nat Commun* **11**, 3581, doi:10.1038/s41467-020-17488-
443 8 (2020).
- 444 13 Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans.
445 *medRxiv*, doi:10.1101/2020.03.17.20037713 (2020).
- 446 14 Robbiani, D. F. *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent
447 individuals. *Nature*, doi:10.1038/s41586-020-2456-9 (2020).
- 448 15 Wang, Y. *et al.* Kinetics of viral load and antibody response in relation to COVID-19
449 severity. *J Clin Invest*, doi:10.1172/JCI138759 (2020).
- 450 16 Liu, A. *et al.* Disappearance of antibodies to SARS-CoV-2 in a Covid-19 patient after
451 recovery. *Clin Microbiol Infect*, doi:10.1016/j.cmi.2020.07.009 (2020).
- 452 17 Barnes, C. O. *et al.* Structures of human antibodies bound to SARS-CoV-2 spike reveal
453 common epitopes and recurrent features of antibodies. *bioRxiv*,
454 doi:10.1101/2020.05.28.121533 (2020).
- 455 18 Dogan, M. *et al.* Novel SARS-CoV-2 specific antibody and neutralization assays reveal
456 wide range of humoral immune response during COVID-19. *medRxiv*,
457 doi:10.1101/2020.07.07.20148106 (2020).

- 458 19 Harcourt, J. *et al.* Isolation and characterization of SARS-CoV-2 from the first US
459 COVID-19 patient. *bioRxiv*, doi:10.1101/2020.03.02.972935 (2020).
- 460 20 Crawford, K. H. D. *et al.* Protocol and Reagents for Pseudotyping Lentiviral Particles
461 with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12**,
462 doi:10.3390/v12050513 (2020).
- 463 21 Zost, S. J. *et al.* Potently neutralizing and protective human antibodies against SARS-
464 CoV-2. *Nature*, doi:10.1038/s41586-020-2548-6 (2020).
- 465 22 Schmidt, F. *et al.* Measuring SARS-CoV-2 neutralizing antibody activity using
466 pseudotyped and chimeric viruses. *J Exp Med* **217**, doi:10.1084/jem.20201181 (2020).
- 467 23 Leung, D. T. *et al.* Antibody response of patients with severe acute respiratory syndrome
468 (SARS) targets the viral nucleocapsid. *J Infect Dis* **190**, 379-386, doi:10.1086/422040
469 (2004).
- 470 24 Shang, J. *et al.* Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A* **117**,
471 11727-11734, doi:10.1073/pnas.2003138117 (2020).
- 472 25 Ravichandran, S. *et al.* Antibody signature induced by SARS-CoV-2 spike protein
473 immunogens in rabbits. *Sci Transl Med* **12**, doi:10.1126/scitranslmed.abc3539 (2020).
- 474 26 Zohar, T. & Alter, G. Dissecting antibody-mediated protection against SARS-CoV-2. *Nat*
475 *Rev Immunol* **20**, 392-394, doi:10.1038/s41577-020-0359-5 (2020).
- 476 27 Wu, L. P. *et al.* Duration of antibody responses after severe acute respiratory syndrome.
477 *Emerg Infect Dis* **13**, 1562-1564, doi:10.3201/eid1310.070576 (2007).
- 478 28 Vabret, N. Antibody responses to SARS-CoV-2 short-lived. *Nat Rev Immunol*,
479 doi:10.1038/s41577-020-0405-3 (2020).
- 480 29 Robbiani, D. F. *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection in
481 Convalescent Individuals. *bioRxiv*, doi:10.1101/2020.05.13.092619 (2020).
- 482 30 Wang, K. *et al.* Longitudinal dynamics of the neutralizing antibody response to SARS-
483 CoV-2 infection. *Clin Infect Dis*, doi:10.1093/cid/ciaa1143 (2020).
- 484 31 Wajnberg, A. *et al.* SARS-CoV-2 infection induces robust, neutralizing antibody
485 responses that are stable for at least three months. *medRxiv*, 2020.2007.2014.20151126,
486 doi:10.1101/2020.07.14.20151126 (2020).
- 487 32 Suhandynata, R. T. *et al.* Commercial Serology Assays Predict Neutralization Activity
488 Against SARS-CoV-2. *medRxiv*, 2020.2007.2010.20150946,
489 doi:10.1101/2020.07.10.20150946 (2020).
- 490 33 Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and Other
491 Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020). *Trends Immunol* **41**,
492 545, doi:10.1016/j.it.2020.04.008 (2020).
- 493 34 Phipps, W. S. *et al.* SARS-CoV-2 Antibody Responses Do Not Predict COVID-19
494 Disease Severity. *Am J Clin Pathol*, doi:10.1093/ajcp/aqaa123 (2020).
- 495 35 Elizaldi, S. R. *et al.* SARS-CoV-2 infection induces germinal center responses with
496 robust stimulation of CD4 T follicular helper cells in rhesus macaques. *bioRxiv*,
497 doi:10.1101/2020.07.07.191007 (2020).
- 498 36 Schultheiss, C. *et al.* Next-Generation Sequencing of T and B Cell Receptor Repertoires
499 from COVID-19 Patients Showed Signatures Associated with Severity of Disease.
500 *Immunity*, doi:10.1016/j.immuni.2020.06.024 (2020).
- 501 37 Peng, Y. *et al.* Broad and strong memory CD4 (+) and CD8 (+) T cells induced by
502 SARS-CoV-2 in UK convalescent COVID-19 patients. *bioRxiv*,
503 doi:10.1101/2020.06.05.134551 (2020).

504 38 Juno, J. A. *et al.* Humoral and circulating follicular helper T cell responses in recovered
505 patients with COVID-19. *Nat Med*, doi:10.1038/s41591-020-0995-0 (2020).

506 39 Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans
507 with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415,
508 doi:10.1016/j.cell.2020.05.015 (2020).

509 40 Channappanavar, R., Zhao, J. & Perlman, S. T cell-mediated immune response to
510 respiratory coronaviruses. *Immunol Res* **59**, 118-128, doi:10.1007/s12026-014-8534-z
511 (2014).

512 41 Altmann, D. M. & Boyton, R. J. SARS-CoV-2 T cell immunity: Specificity, function,
513 durability, and role in protection. *Sci Immunol* **5**, doi:10.1126/sciimmunol.abd6160
514 (2020).

515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548

Extended Data Table 1: SARS-CoV-2 positive NYU healthcare worker information and data used in this study.

COVID-19 Patient #	Sympt. onset date	Days post sympt. onset	Anti-N ELISA*			Anti-RBD ELISA**			Neutralization SARS-CoV-2	Neutralization Pseudotyped virus	
			IgG	IgA	IgM	IgG	IgA	IgM		1/MIC	1/IC90
1	3/16/20	43	31.59	5.54	24.32	2.152	0.344	0.211	40	44.9	108
2	3/18/20	41	18.14	0.58	9.26	0.892	0.244	0.217	20	32.83	125
3	3/17/20	42	38.76	3.6	5.58	2.943	0.927	0.257	160	127.7	361
4	3/12/20	47	9.24	0.43	0.71	1.921	0.214	0.209	20	27.7	61
5	3/20/20	39	7.56	0.77	4.42	0.88	0.19	0.202	40	18.69	44
6	3/19/20	40	37.18	4.03	11.76	2.857	0.545	0.441	80	57.75	121
7	3/15/20	44	17.47	0.31	1.97	2.627	0.183	0.204	40	42.9	121
8	3/19/20	40	7.58	3.54	19.43	2.068	0.987	0.216	40	40.93	95
9	3/8/20	51	27.15	2.92	12.8	2.666	0.345	0.532	80	64.58	181
10	3/18/20	41	41.83	3.23	16.48	2.848	1.314	2.514	320	120.4	1094
11	3/17/20	42	24.15	1.14	10	1.783	0.338	0.466	40	16.5	59
12	3/11/20	48	37.95	5.78	1.52	2.281	0.507	0.437	80	22.88	94
13	3/9/20	50	41.84	45.02	35.09	2.993	3.364	3.296	2560	157.1	1919
14	3/17/20	42	24.4	0.74	4.53	2.301	0.555	0.31	80	12.31	77
15	3/16/20	43	23.79	1.11	6.15	2.452	0.583	1.811	160	40.52	107
16	3/19/20	40	7.29	3.29	6.7	2.068	1.041	0.553	40	18.01	97
17	3/28/20	41	15.5	17.09	12.11	1.008	0.178	0.616	40	50.47	163
18	3/13/20	46	29.12	4.8	33.01	1.532	0.379	0.829	160	58.97	170
19	3/24/20	35	5.98	0.95	4.73	1.091	0.204	0.328	40	20.99	91
20	3/20/20	39	17.41	5.26	25.58	2.788	0.501	0.773	160	86.11	282
21	3/18/20	41	5.09	1.08	1.66	1.388	0.233	0.295	40	17.51	63
22	3/20/20	39	37.97	95.17	19.05	3.064	2.564	1.312	640	187.3	4752
23	3/4/20	55	37.55	11.99	25.16	2.708	0.414	0.285	80	88.19	299
24	3/2/20	57	12.97	0.52	19.24	2.068	0.328	0.482	80	33.73	305
25	3/6/20	53	34.37	0.52	5.2	1.846	0.307	0.44	40	26.55	116
26	3/23/20	36	13.11	1.51	1.09	2.114	0.275	0.222	20	10.23	92
27	3/20/20	39	7.6	0.34	9.31	1.712	0.338	0.351	20	13.78	52
28	3/24/20	35	17.53	1.08	5.92	1.884	0.707	0.399	40	26.87	91
29	3/25/20	34	32.97	2.34	16.96	2.764	2.091	3.035	160	77.9	195
30	3/22/20	37	32.52	5.29	3.18	2.772	1.522	0.74	80	62.62	221
31	3/20/20	39	6.22	4.4	3.64	1.471	0.532	0.335	20	13.31	65
32	3/20/20	39	26.69	4.03	15.65	2.457	3.034	0.956	160	37.89	131
33	3/20/20	39	21.03	1.2	3.09	1.752	0.209	0.455	40	63.95	182
34	3/21/20	38	50.25	9.56	39.24	2.848	3.452	2.398	640	175.9	1509
35	3/23/20	36	22.76	1.2	6.1	1.469	0.584	0.896	160	38.32	117
36	3/16/20	43	4.01	0.86	3.96	1.528	0.37	0.519	40	49.28	145
37	3/15/20	44	6.89	0.86	10.95	0.898	0.594	0.472	Neg	7.66	34
38	3/19/20	40	16.11	0.49	11.15	2.11	0.303	0.177	40	40.05	150
39	3/21/20	38	29.52	2.77	5.28	2.602	1.752	0.796	80	73.12	272
40	3/19/20	40	6.5	1.26	2.85	1.203	0.228	0.443	20	3.33	36
41	3/15/20	44	34.99	0.65	4.28	1.76	0.313	0.582	40	20.6	92
42	3/16/20	43	5.59	0.58	11.97	1.804	0.274	0.602	40	42.1	248
43	3/24/20	35	32.38	4.74	18.91	2.019	0.48	0.706	80	42.33	152
44	3/14/20	45	32.36	1.14	8.27	1.829	0.761	0.413	20	25.9	88
45	3/19/20	40	40.06	0.74	1.43	1.624	0.255	0.382	80	25.36	121
46	3/16/20	43	15.22	1.26	17.94	1.778	0.35	0.834	80	30.3	122
47	3/20/20	39	27.9	3.38	13.16	1.664	0.404	0.713	40	3.04	60
48	3/20/20	39	24.34	0.68	6.93	1.468	0.289	1.293	160	38.18	345
49	3/19/20	40	19.7	6.86	1.74	1.965	0.53	0.278	40	35.9	148
50	3/27/20	32	15.54	1.08	2.38	2.191	0.487	0.113	80	30.31	137
51	3/23/20	36	24.6	1.6	10.88	2.221	0.223	0.272	80	18.7	83

52	3/27/20	32	36.07	4.15	20.35	2.896	1.079	0.484	80	41.24	235
53	3/15/20	44	41.3	3.81	3.39	2.701	0.723	1.381	320	77.67	1101
54	3/20/20	39	56.66	1.97	5.68	2.703	0.317	0.844	320	55.85	765
55	3/19/20	40	13.23	0.74	9.83	1.094	0.139	0.479	40	0.776	10
56	3/19/20	40	11.12	1.48	7.88	1.977	0.215	1.641	40	15.02	53
57	3/18/20	41	12.85	5.14	11.17	0.977	0.287	0.582	20	13.61	38
58	3/26/20	33	41.54	4.27	13.32	2.754	0.363	0.927	160	77.31	243
59	3/19/20	40	46.08	4.55	7.03	2.985	0.436	0.781	80	21.98	524
60	3/14/20	45	18.7	4.74	31.09	1.714	0.411	0.399	40	11.49	48
61	3/20/20	39	27.36	4.89	10.22	2.872	2.197	2.89	640	321.3	785
62	3/23/20	36	31.91	0.92	5.15	3.227	0.974	1.667	160	98.68	1729
63	3/18/20	41	39.41	15.62	13.18	1.967	0.308	0.421	40	1.105	27
64	3/15/20	44	15.48	0.86	2.49	1.874	0.248	1.104	40	54.83	253
65	3/22/20	37	6.26	1.41	15.27	0.598	0.282	0.344	20	9.62	36
66	3/20/20	39	26.32	1.91	17.7	2.08	0.324	0.64	160	60.52	239
67	3/9/20	50	42.07	2.89	6.98	2.971	0.706	1.04	640	227.7	577
68	3/6/20	53	12.03	0.52	1.5	1.261	0.301	0.372	40	16.19	88
69	3/26/20	33	15.64	10.42	2.97	1.818	0.516	0.369	40	21.06	56
70	3/21/20	38	33.25	2.86	5.03	3.209	1.252	1.078	320	118.5	420
71	3/26/20	33	22.59	0.71	11.9	2.768	0.768	0.45	40	27.79	94
72	3/23/20	36	25.07	1.91	6.49	2.906	0.329	1.275	160	54.04	149
73	3/19/20	40	21.05	0.55	1.55	1.84	0.181	0.388	40	72.73	178
74	3/21/20	38	12.26	0.98	6.55	0.525	0.175	0.514	20	26.93	88
75	3/24/20	35	6.79	0.62	2.02	1.73	0.121	0.272	20	15.35	52
76	3/23/20	36	40.43	2.95	16.96	nd	nd	nd	80	90.81	324
77	3/16/20	43	22.11	0.4	4.51	2.205	0.364	0.907	40	50.05	158
78	3/22/20	37	51.14	7.93	52.71	3.197	1.149	1.417	320	86.66	716
79	3/26/20	33	11.02	0.31	4.09	0.829	0.171	0.771	40	12.67	60
80	3/20/20	39	20.06	0.31	3.56	2.665	0.421	0.801	40	50.24	171
81	3/22/20	37	2.43	2.37	2.71	0.76	0.121	0.399	Neg	7.09	35
82	3/24/20	35	19.35	1.11	21.83	0.603	0.257	0.659	20	neg	neg
83	3/26/20	33	37.87	8.49	52.71	3.265	3.204	1.204	320	152.8	2819
84	3/26/20	33	41.3	35.55	52.71	3.184	2.454	2.725	1280	195.1	538
85	3/19/20	40	10.9	2.12	3.26	1.819	0.177	0.191	20	51.81	132
86	3/24/20	38	10.92	1.01	6.65	nd	nd	nd	20	9.92	49
87	3/17/20	45	7.98	2.31	5.82	1.571	0.176	0.923	20	26.96	83
88	3/8/20	54	38.89	3.91	23.07	2.794	0.391	1.079	80	63.96	250
89	3/26/20	36	53.11	15.04	5.13	3.066	1.041	0.639	320	115.4	465
90	3/22/20	40	30.4	3.47	7.82	3.019	0.205	0.461	80	96.81	311
91	3/15/20	47	12.26	0.55	1.78	0.82	0.094	0.326	20	4.66	36
92	3/27/20	35	19.63	0.72	2.41	2.257	0.488	0.305	40	42.43	135
93	3/17/20	45	29.03	0.74	2.17	2.861	0.671	0.735	80	92.69	270
94	3/28/20	34	15.73	3.75	4.75	2.471	0.384	0.454	80	85.51	218
95	3/20/20	42	31.75	2.45	5.49	2.493	0.296	0.532	40	31.98	125
96	3/20/20	42	28.53	2.27	11.82	2.777	0.899	0.729	80	47.39	176
97	3/25/20	37	33.44	31.98	4.32	2.419	0.351	0.536	80	47.98	170
98	3/19/20	43	20.89	1.54	8.85	1.913	0.602	0.612	40	12.62	55
99	3/13/20	49	36.93	4.47	8.72	2.463	1.887	0.583	160	54.63	299
100	3/28/20	34	18.94	6.92	6.99	1.122	0.347	0.339	40	21	111
101	3/27/20	35	4.99	1.54	2.33	0.796	0.147	0.261	20	23.55	68

*Threshold for Anti-NP ELISA (IgG, IgM, IgA OD₄₅₀ < 9).

**Threshold for Anti-RBD ELISA (-IgG is OD_{490nm} = 1.091; -IgM is OD_{490nm} = 0.256 and -IgA is OD_{490nm} = 0.694). nd. measures not included in the analysis.




Figure 1. SARS-CoV-2 neutralizing antibody response. **a.** Schematic representation of the experimental design. **b.** Correlation analysis of the sera neutralization level of 101 COVID-19 convalescent patients. The data presented are the log₂ of the neutralization titer against the authentic SARS-CoV-2 virus (1/MIC) and the pseudotyped virus (1/IC₉₀). Correlation and linear regression analyses were performed using GraphPad Prism 8. P values were calculated using a two-sided F-test. **c.** SARS-CoV-2 neutralization categories. Sera of convalescent patients was defined as low (dil:1/10 to 1/80), intermediate (dil:1/81 to 1/639) and high (dil > 1/640) based on authentic SARS-CoV-2 virus (blue box) or pseudotyped virus (red box). P values were calculated using two-sided Fisher's exact test. **d.** Rank of the absolute differences in neutralization capacity from sera of 101 COVID-19 convalescent patients. Neutralization titers against SARS-CoV-2 virus (blue) or pseudotyped virus (red) was ordered based on the absolute difference between 1/MIC and 1/IC₉₀. Dashed lines indicate the different neutralization categories. The gray box highlights those samples with the highest absolute difference in the neutralization capacity between SARS-CoV-2 virus (blue) or pseudotyped virus (red). **e.** Distribution of authentic SARS-CoV-2 virus neutralization titers (1/MIC) over days post symptom onset. Dashed lines indicate the neutralization levels as defined in panel B. White dots indicate two individuals with SARS-CoV-2 non-neutralizing sera.




Figure 2. Isotype composition of SARS-CoV2 convalescent serum. Anti-RBD and anti-N ELISA correlation for IgG (a), IgM (b) and IgA (c). Left panels: Correlations and linear regressions comparing anti-RBD and anti-N for each antibody isotype (N=101). Analyses were performed using GraphPad Prism 8. P values were calculated using a two-sided F-test. The red dashed lines indicate the threshold (anti-N ELISA for -IgG, -IgM or -IgA are OD_{450nm} = 9; anti-RBD ELISA for -IgG is OD_{490nm} = 1.091; -IgM is OD_{490nm} = 0.256 and -IgA is OD_{490nm} = 0.694) for each ELISA. Right panels indicate the percentage of COVID-19 PCR-positive patients that are positive (blue bars) or negative (gray bars) for IgG (a), IgM (b) or IgA (c). P values were calculated using two-sided Fisher's exact test.




Figure 3. Correlation of anti-RBD antibody isotypes with viral neutralization. Anti-RBD ELISA correlation for IgG (top), IgA (Middle) and IgM (Bottom) with viral neutralization using authentic SARS-CoV-2 (a) or Pseudotyped virus (b). Correlation and linear regression analyses were performed using GraphPad Prism 8. P values were calculated using a two-sided F-test. The red dashed lines indicate the threshold (anti-RBD ELISA for -IgG is OD_{490nm} = 1.091; -IgM is OD_{490nm} = 0.256 and -IgA is OD_{490nm} = 0.694) for each ELISA.





Figure 4. Identification of serological signatures for neutralization. Heatmap of anti-RBD (a) and anti-N (b) antibody isotype ELISA titers and corresponding authentic SARS-CoV-2 neutralization. Serological data from the 101 COVID-19 patients was ranked from low to high neutralization. Sera of convalescent patients was defined as low (dil:1/10 to 1/80), intermediate (dil:1/81 to 1/639) and high (dil > 1/640). Red bar indicates those COVID-19 patients with high neutralizer antibodies. c. Correlation analysis of anti-RBD IgM vs IgG (left panel), anti-RBD IgA vs IgG (middle panel) and anti-RBD IgA vs IgM (right panel). d. Correlation analysis of anti-N IgM vs IgG (left panel), anti-N IgA vs IgG (middle panel) and anti-N IgA vs IgM (right panel). For (c) and (d) correlation and linear regression analyses were performed using the linear model function in R (lm). P values were calculated using a two-sided F-test. The size of the dots indicates the MIC and the color of the dots indicates the neutralization category: High (red dots), Intermediate (blue) and Low (gray) as determined using authentic SARS-CoV-2 neutralization (see Fig. 2 legend).

a.



b.







Figure 5. Clustering analysis of individual SARS-CoV-2 antibody response. a. Combination of antibody isotypes in individual patient sera defining different cluster classes. ELISA titers were categorized as positive (ELISA titers > cutoff) or negative (ELISA titer < cutoff) for each sample for each individual antibody isotype. Clusters were made based on the presence or absence of specific isotypes (Cluster A to U). The number of patients in each cluster is shown on the x axis. b. Neutralization levels shown for each individual antibody cluster.




Extended Data Figure. 1. Production of SARS-CoV-2 Spike RBD antigen and characterization of anti-RBD ELISA. **a.** SDS-PAGE of purified RBD-His6-Avi-biotin using the Bio-Rad stain-free detection method. Lane M contains standards with its molecular weight in kDa. **b.** Purified RBD-His6-Avi-biotin size-exclusion chromatography on a Superdex 75 10/300 Increase column detected using absorbance at 280 nm. The elution positions of molecular weight standards are marked as bars with their molecular weights in kDa. **c.** Determination of ELISA thresholds. Serum from the 101 SARS-CoV-2 PCR positive were diluted 1/158 and 1/500 and compared with 43 SARS-CoV-2 PCR negative individuals. The cutoff values were defined as the mean plus three times the standard deviation (SD) of the negative control samples as shown by the red arrow. The dashed line indicates the position of each individual cutoff. Cutoff values are indicated in red. **d.** Table showing the sensitivity (% of true positive in positive) and specificity (% of true negative in negative) of each RBD antibody subtype and dilution.



Extended Data Figure 2. Individual sera neutralization of pseudotyped virus. Pseudotyped virus was mixed 1:1 with 2-fold dilutions of individual sera and incubated at room temperature for 30 minutes before infecting ACE2-293T cells. Relative infection was determined by luciferase expression 48 hrs post-incubation. Data is represented as the percentage of the untreated control. Data was fitted to a variable slope model $\log(\text{serum dilution})$ versus response using Graph Pad prism.



Extended Data Figure 3. Correlations between isotype composition of SARS-CoV-2 convalescent serum and days post onset of symptoms. Correlations of anti-RBD (top) or anti-N (bottom) IgG (a), IgM (b) and IgA (c) over days post onset of symptoms are shown. Quartiles were defined based on positive samples (data points > cutoff) for anti-RBD IgG. Each quartile has the following number of observations: anti-RBD IgG (n= 29, 30, 18, 22), anti-N IgG (n= 11, 13, 5, 8), anti-RBD IgM (n= 23, 20, 15, 17), anti-N IgM (n= 11, 12, 10, 8), anti-RBD IgA (n= 24, 28, 15, 20), anti-N IgA (n= 4, 2, 2, 2). P values were calculated using the Wilcoxon rank sum test. The red dashed lines indicate the threshold (anti-N ELISA for -IgG, -IgM or -IgA are OD450nm = 9; anti-RBD ELISA for -IgG is OD490nm = 1.091; -IgM is OD490nm = 0.256 and -IgA is OD490nm = 0.694) for each ELISA.



Extended Data Figure 4. Correlation of anti-N antibody isotypes with viral neutralization.

Anti-N ELISA correlation for IgG (top), IgA (Middle) and IgM (Bottom) with viral neutralization using authentic SARS-CoV-2 (a) or Pseudotyped virus (b). Correlation and linear regression analyses were performed using GraphPad Prism 8. P values were calculated using a two-sided F-test. The red dashed lines indicate the threshold (anti-RBD ELISA for -IgG; -IgM and -IgA is OD_{450nm} > 9) for each ELISA.